Watchdog Calls FDA Approval of Psychotropics & Electroshock Conflict of Interest

The FDA’s continuing clearance of potentially dangerous psychotropic drugs and electroshock devices fuels a lucrative $35 billion a year industry.

Clearwater, United States - March 14, 2019 /PressCable/ —

The Food and Drug Administration (FDA) is considering approving Johnson & Johnson’s (J&Js) new nasal spray antidepressant, esketamine (Spravato) after an FDA advisory committee voted on February 12, 2019 in its favor. The drug is a chemical mirror of ketamine, a potent “dissociative anesthetic” that is abused as the illegal “club drug,” Special K, and generates an intense high and euphoric effects, and hallucinations. If approved, it would add to the mind-numbing of America that an FDA-psychiatric collusion is causing, says the Citizens Commission on Human Rights (CCHR). The group said the FDA’s continuing clearance of potentially addictive and dangerous psychotropic drugs and, more recently, electroshock treatment devices, fuels a lucrative $35 billion a year industry at the cost of consumers’ mental health and lives. [1] [2]

Astoundingly, with more than 43.6 million Americans each year now taking antidepressants once touted as “miracle pills,” psychiatrists now claim that the drugs don’t work in one out of every three people taking them. It was known when the drugs were approved that they could cause suicidal thoughts and violence-related effects—hardly a recipe for improving depression. Mental health watchdog CCHR, says psychiatrists often also recommend electroshock treatment—up to 460 volts of electricity sent through the brain to cause a grand-mal seizure—when antidepressants and other psychopharmaceuticals fail.

Jan Eastgate, president of CCHR International, says: “ECT is recommended for ‘treatment-resistant depression,’ a term invented to mislead consumers into thinking the problem is theirs and not the failure of psychiatric treatments. Despite the failure, the serious and deadly risks of treatment and a history of manufacturers covering up adverse effects, the FDA keeps giving them license to profit.”

Between 1988 and 2005, the FDA approved nine new antidepressants and five new antipsychotics. At least four more antidepressants have been approved since 2010. Drug companies provide 60% of the FDA’s drug review costs—a colossal conflict of interest—representing more than $712 million a year in revenue. There’s another estimated $24 million for medical device clearance. [3] [4] [5] [6]

This adds to a lucrative mental health market. Spending on non-institutionalized mental disorder treatment accounted for $89 billion in 2013. The up to 90% prevalence of polypharmacy in psychiatry—prescribing a patient multiple drugs—would contribute to those costs. [7] [8]

Esketamine is but another touted “hopeful” drug that will merely mask—but not cure—depression. The nasal spray would be given with an antidepressant. Several side effects of esketamine are dissociation and sedation, prompting the FDA advisory panel to recommend not allowing people to take the nasal spray at home but remain monitored in a healthcare facility for two hours until these side effects subside. [9] [10]

There’s been a boom in the off-label (non-FDA approved) use of ketamine as a treatment for depression and other psychiatric conditions. Dozens of for-profit ketamine clinics have opened up around the country, including in Florida. The clinics regularly charge $650 – $1,200 per treatment, with most people needing six – eight treatments (up to $9,600) to get started. [11] [12] [13]

J&J anticipates $1 billion-plus in sales from a crop of new drugs that includes esketamine. This won’t recoup the costs it has paid in settlements of lawsuits over its antipsychotic, Risperdal (risperidone) and a $2.2 billion Department of Justice fine over marketing and selling Risperdal and other drugs off-label. J&J has paid out millions of dollars to settle lawsuits about its failure to warn that Risperdal can cause gynecomastia (male breast growth). One youth was awarded $70 million in damages after alleging Risperdal caused him to grow size 42D breasts. None of this appears to be of concern to FDA officials or psychiatrists advocating for yet another brain-altering drug. [14] [15]

The FDA has also approved antipsychotics as adjuncts to antidepressants when they’ve failed. Studies show aripiprazole (Abilify), olanzapine/fluoxetine (Symbyax), quetiapine (Seroquel) and risperidone (Risperdal) have been used with antidepressants. Yet a study by Glen Spielmans, Ph.D., a researcher and associate professor of psychology at Metropolitan State University in St. Paul, found that in “terms of quality of life and how well people were functioning, there was really not much evidence that these drugs did anything.” There was “abundant evidence of potential treatment-related harm,” including weight gain, akathisia (uncontrollable restlessness), and abnormal results from cholesterol and other metabolic-related laboratory tests. [16]

Now add to these chemical bombs, electroshock. This has an up to 70% failure (relapse) rate within six months of receiving it. Antidepressants are continued with ECT. [17]

Diane Stein, president of CCHR Florida, who is investigating psychotropic drug use and electroshock in Florida, said the level of misrepresentation about these treatments’ risks starts with psychiatry and runs through the FDA and at state level. “University of Florida Health recommends maintenance ECT up to every two to three months, while asserting that it works by making the brain ‘rewire’ itself—without any scientific evidence to support this. Concurrent psychiatric drugs are usual practice, which is simply evidence that ECT doesn’t work.”

Eastgate and Stein say the FDA’s approval process needs investigating, including its collusion with psychiatric organizations pushing drugs and electroshock—a combination that puts industry interests above patient protection. They urge people to support a ban on ECT in Florida (petition) and nationally.

About CCHR: Initially established by the Church of Scientology and renowned psychiatrist Dr. Thomas Szasz in 1969, CCHR’s mission is to eradicate abuses committed under the guise of mental health and enact patient and consumer protections. L. Ron Hubbard, founder of Scientology, first brought psychiatric imprisonment to wide public notice: “Thousands and thousands are seized without process of law, every week, over the ‘free world’ tortured, castrated, killed. All in the name of ‘mental health,’” he wrote in March 1969. For more information visit www.cchrflorida.org

Please click here for references.

Contact Info:
Name: Diane Stein
Email: Send Email
Organization: Citizens Commission on Human Rights of Florida
Address: 109 North Fort Harrison Avenue, Clearwater, Florida 33755, United States
Phone: +1-727-442-8820
Website: http://www.cchrflorida.org/

Source: PressCable

Release ID: 492155

Latest News

US judge denies bail for ex-Peruvian president Toledo

Jul 19, 2019

SAN FRANCISCO — A U.S. judge on Friday denied bail for former Peruvian President Alejandro Toledo after prosecutors argued he was a flight risk and pointed out officials found a suitcase with $40,000 in cash during his arrest. Magistrate Judge Thomas S. Hixson ordered Toledo, 73, held pending an extradition hearing scheduled for July 26. U.S. Marshals detained Toledo at his Northern California home Tuesday on an extradition request. The ex-president is wanted in his home country on accusations of taking $20 million in bribes from Brazilian construction company Odebrecht. Toledo denies the charges. Assistant U.S. Attorney Elise Lapunzina told...

Judge weighs new Motel 6 settlement in immigration lawsuit

Jul 19, 2019

PHOENIX — A revised settlement for Motel 6 guests who say the national chain invaded their privacy by giving their information to immigration authorities is returning to court Friday for a judge's review. A federal judge is to decide during an afternoon hearing on the new proposal making $10 million available for awards to claims by members of the class action suit. A class member could get $75 if they were a registered guest, up to $10,000 if they were placed in deportation proceedings as a result of having their information shared and as much as $200,000 if a person...

The Latest: Iran claims video proves drone wasn't shot down

Jul 19, 2019

TEHRAN, Iran — The Latest on developments related to tensions between the U.S and Iran (all times local): 9:25 p.m. Iran's Revolutionary Guard has released video images it claims proves that a U.S. warship did not destroy an Iranian drone near the Persian Gulf. Iranian state TV shows video it says was taken by an Iranian drone on Thursday of the USS Boxer and another American warship. The IRG on its website said the drone recorded three hours of video of the USS Boxer and five other vessels Thursday starting when the ships first entered the Strait of Hormuz. Trump...

Giant Hawaii telescope to focus on big unknowns of universe

Jul 19, 2019

HONOLULU — Is there life on planets outside our solar system? How did stars and galaxies form in the earliest years of the universe? How do black holes shape galaxies? Scientists are expected to explore those and other fundamental questions about the universe when they peer deep into the night sky using a new telescope planned for the summit of Hawaii's tallest mountain. But the Thirty Meter Telescope is a decade away from being built. And Native Hawaiian protesters have tried to thwart the start of construction by blocking a road to the mountain. They say installing yet another observatory...

UK lawmakers warn citizens' rights at risk in no-deal Brexit

Jul 19, 2019

BRUSSELS — British lawmakers met the European Union's chief Brexit negotiator on Friday, seeking an iron-clad guarantee that the 1.3 million U.K. citizens in the bloc won't have their rights removed and their lives disrupted if Britain leaves the EU without a deal. The rights of U.K. citizens living in the 27 other EU nations, and those of the more than 3 million EU citizens in Britain, are one of the thorniest issues of the Brexit negotiations. Their rights to live, work and study are protected under an agreement struck between the two sides — but the divorce agreement has...

Search

Deck Biz is an intelligent platform providing international and regional business news updates. You won’t get these insights elsewhere other than Deck Biz.

Contact us: sales@deckbiz.com